INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 49 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2014. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $489,000 | +40.9% | 30,965 | +10.9% | 0.00% | +100.0% |
| Q2 2017 | $347,000 | -17.4% | 27,928 | +8.1% | 0.00% | -50.0% |
| Q1 2017 | $420,000 | +1.2% | 25,829 | -6.1% | 0.00% | 0.0% |
| Q4 2016 | $415,000 | +21.0% | 27,510 | +22.3% | 0.00% | +100.0% |
| Q3 2016 | $343,000 | -60.7% | 22,497 | 0.0% | 0.00% | -75.0% |
| Q2 2016 | $873,000 | +81.9% | 22,497 | +30.2% | 0.00% | +100.0% |
| Q1 2016 | $480,000 | -48.6% | 17,274 | -0.4% | 0.00% | -50.0% |
| Q4 2015 | $933,000 | +65.7% | 17,341 | +23.4% | 0.00% | +33.3% |
| Q3 2015 | $563,000 | +25.4% | 14,051 | 0.0% | 0.00% | +50.0% |
| Q2 2015 | $449,000 | +42.5% | 14,051 | +6.7% | 0.00% | +100.0% |
| Q1 2015 | $315,000 | +38.2% | 13,171 | +1.8% | 0.00% | 0.0% |
| Q4 2014 | $228,000 | +26.7% | 12,932 | -1.3% | 0.00% | 0.0% |
| Q3 2014 | $180,000 | -17.4% | 13,101 | +1.4% | 0.00% | 0.0% |
| Q2 2014 | $218,000 | – | 12,924 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |